Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of January 25, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic?focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and distributed through Harrow’s wholly owned subsidiary, ImprimisRx, combined with the Company’s existing ophthalmic?focused product portfolio, support Harrow’s growing ophthalmic surgical and acute care market presence.
Bliss GVS Pharma Limited is on FDA Import Alert List
The novel coronavirus pandemic has caused a host of problems in the global pharmaceutical supply chain—particularly in China, a major producer of drug ingredients. Now, seeing an opportunity, India is reportedly working on a plan to supersize its own ingredient manufacturing to combat Chinese dominance in the market.
While eyes have been on China for signs that COVID-19 might result in drug shortages, India has come up with a surprise of its own. The country, which accounts for about 40% of U.S. generic drugs, has halted exports of more than two dozen APIs and drugs.
Coronavirus: Dept of Pharma asks DGFT to restrict export of 12 drug ingredients, formulations
Coronavirus: Department of Pharmaceuticals recommends ban on export of 12 drug formulations, ingredients
Enforcement Report - Week of November 6, 2019
Enforcement Report - Week of August 7, 2019